Kelly Symmes
Overview
Explore the profile of Kelly Symmes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ullah I, Symmes K, Keita K, Zhu L, Grunst M, Li W, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340037
Virus-like particles (VLPs) are non-infectious and serve as promising vaccine platforms because they mimic the membrane-embedded conformations of fusion glycoproteins on native viruses. Here, we employed SARS-CoV-2 VLPs (SMEN) presenting...
2.
Ullah I, Beaudoin-Bussieres G, Symmes K, Cloutier M, Ducas E, Tauzin A, et al.
Cell Rep Med
. 2022 Dec;
4(1):100893.
PMID: 36584683
COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that promote SARS-CoV-2 control are complex and incompletely defined. Using...
3.
Beaudoin-Bussieres G, Chen Y, Ullah I, Prevost J, Tolbert W, Symmes K, et al.
Cell Rep
. 2022 Feb;
38(7):110368.
PMID: 35123652
Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector functions alone can protect against SARS-CoV-2. Here, we...
4.
Ullah I, Prevost J, Ladinsky M, Stone H, Lu M, Anand S, et al.
Immunity
. 2021 Aug;
54(9):2143-2158.e15.
PMID: 34453881
Neutralizing antibodies (NAbs) are effective in treating COVID-19, but the mechanism of immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) to monitor the real-time effects...
5.
Rajashekar J, Richard J, Beloor J, Prevost J, Anand S, Beaudoin-Bussieres G, et al.
Cell Host Microbe
. 2021 May;
29(6):904-916.e6.
PMID: 34019804
Small CD4-mimetic compounds (CD4mc) sensitize HIV-1-infected cells to antibody-dependent cellular cytotoxicity (ADCC) by facilitating antibody recognition of epitopes that are otherwise occluded on the unliganded viral envelope (Env). Combining CD4mc...
6.
Ullah I, Prevost J, Ladinsky M, Stone H, Lu M, Anand S, et al.
bioRxiv
. 2021 Apr;
PMID: 33791699
Neutralizing antibodies (NAbs) are effective in treating COVID-19 but the mechanism of immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) to monitor the real-time effects...
7.
Chiu C, Coffey L, Murkey J, Symmes K, Sample H, Wilson M, et al.
Emerg Infect Dis
. 2017 Sep;
23(10):1964-1968.
PMID: 28930022
We used unbiased metagenomic next-generation sequencing to diagnose a fatal case of meningoencephalitis caused by St. Louis encephalitis virus in a patient from California in September 2016. This case is...
8.
White G, Symmes K, Sun P, Fang Y, Garcia S, Steiner C, et al.
Emerg Infect Dis
. 2016 Nov;
22(12):2185-2188.
PMID: 27869600
St. Louis encephalitis virus infection was detected in summer 2015 in southern California after an 11-year absence, concomitant with an Arizona outbreak. Sequence comparisons showed close identity of California and...